Biogen
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...
Adult Spinal Muscular Atrophy (SMA) China Registry
- Conditions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 200
- Registration Number
- NCT05618379
- Locations
- ๐จ๐ณ
The First People's Hospital of Yunnan Province, Kunming, Yunnan, China
๐จ๐ณHuashan Hospital, Fudan University, Shanghai, Shanghai, China
๐จ๐ณPeking Union Medical College Hospital, Beijing, Beijing, China
A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec
- Conditions
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Biogen
- Target Recruit Count
- 62
- Registration Number
- NCT05575011
- Locations
- ๐ณ๐ฑ
Centre For Human Drug Research, Leiden, Netherlands
๐ณ๐ฑUMC Utrecht, Utrecht, Netherlands
๐ซ๐ทHรดpital Armand Trousseau, Paris, France
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1
- Registration Number
- NCT05532163
- Locations
- ๐ฉ๐ช
Neurologische Studiengesellschaft Bonn GbR, Bonn, Germany
๐ฉ๐ชNeurologische Praxis Dr. med. Boris-Alexander Kallmann, Bamberg, Germany
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)
- Conditions
- Interventions
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Biogen
- Target Recruit Count
- 474
- Registration Number
- NCT05531565
- Locations
- ๐บ๐ธ
Essential Dermatology, Natick, Massachusetts, United States
๐บ๐ธBeacon Clinical Research, LLC, Quincy, Massachusetts, United States
๐บ๐ธUniversity of Massachusetts, Worcester, Worcester, Massachusetts, United States
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
- Conditions
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 7
- Registration Number
- NCT05418673
- Locations
- ๐บ๐ธ
Rocky Mountain Movement Disorders Center, PC, Englewood, Colorado, United States
๐บ๐ธParkinson's Disease and Movement Disorders Center, Boca Raton, Florida, United States
๐บ๐ธPennsylvania Hospital, Philadelphia, Pennsylvania, United States
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 416
- Registration Number
- NCT05399888
- Locations
- ๐บ๐ธ
Mary S. Easton Center for Alzheimer's Disease Research, UCLA, Los Angeles, California, United States
๐บ๐ธUniversity of California San Diego Medical Center, San Diego, California, United States
๐บ๐ธUniversity of California San Francisco (PARENT), San Francisco, California, United States
A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Biogen
- Target Recruit Count
- 864
- Registration Number
- NCT05352919
- Locations
- ๐จ๐ณ
Jiujiang No.1 People's Hospital, Jiujiang, Jiangxi, China
๐ฌ๐ทNNA Hospital, Athens, Attica, Greece
๐บ๐ธWallace Rheumatic Study Center, Beverly Hills, California, United States
Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy
- Conditions
- Interventions
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 62
- Registration Number
- NCT05354414
- Locations
- ๐ซ๐ท
Research SIte, Angers, France
๐ซ๐ทResearch Site, Toulouse, France
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
- Conditions
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 640
- Registration Number
- NCT05348785
- Locations
- ๐บ๐ธ
Invicro, New Haven, Connecticut, United States
๐ฌ๐งRe:Cognition Health Ltd (London), London, Greater London, United Kingdom
๐ฌ๐งRe:Cognition Health - Birmingham, Birmingham, West Midlands, United Kingdom
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1512
- Registration Number
- NCT05310071
- Locations
- ๐บ๐ธ
University of Maryland Medical Center, Baltimore, Maryland, United States
๐บ๐ธMary S. Easton Center for Alzheimer's Disease Research, UCLA, Los Angeles, California, United States
๐บ๐ธUT Southwestern Medical Center, Dallas, Texas, United States